Comprehensive Stock Comparison
Compare XOMA Royalty Corp. (XOMA) vs Vertex Pharmaceuticals Incorporated (VRTX) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  XOMA | 498.7% revenue growth vs REGN's 1.0% |
| Value |  REGN | Lower P/E (17.4x vs 24.7x), PEG 2.75 vs 2.98 |
| Quality / Margins | XOMA | 41.1% net margin vs VRTX's 31.3% |
| Stability / Safety |  VRTX | Beta 0.44 vs XOMA's 0.82, lower leverage |
| Dividends | XOMA | 1.8% yield, vs REGN's 0.4% |
| Momentum (1Y) | XOMA | +22.5% vs VRTX's -2.8% |
| Efficiency (ROA) | VRTX | 14.8% ROA vs XOMA's 7.3%, ROIC 22.8% vs -37.6% |
Who Each Stock Is For
Income & stability
REGNDividend streak 1 yrs, beta 0.58, yield 0.4%
Growth exposure
VRTXRev growth 8.9%, EPS growth 8.4%, 3Y rev CAGR 10.4%
Long-term compounding (10Y)
VRTX425.4% 10Y total return vs REGN's 94.0%
Sleep-well-at-night portfolio
VRTXLower volatility, beta 0.44, Low D/E 19.8%, current ratio 2.90x
Valuation efficiency (growth/$)
REGNPEG 2.75 vs VRTX's 2.98
Defensive / Recession hedge
XOMABeta 0.82, yield 1.8%, current ratio 5.15x
Business Model
What each company does and how it makes money
XOMA Royalty Corp is a biotechnology royalty aggregator that acquires future economic rights to pre-commercial therapeutic candidates licensed to pharmaceutical partners. It generates revenue primarily through milestone payments and royalties from its portfolio of approximately 70 early to mid-stage clinical assets—typically earning a percentage of future drug sales if the therapies succeed. The company's moat lies in its specialized expertise in evaluating clinical-stage assets and structuring royalty agreements that provide diversified exposure to potential blockbuster drugs without bearing development costs.
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing transformative medicines for serious diseases, with its flagship franchise targeting cystic fibrosis. It generates nearly all its revenue from CF therapies — primarily Trikafta/Kaftrio — while building a pipeline in pain, kidney disease, and type 1 diabetes. Its moat stems from deep scientific expertise in CFTR biology and a dominant, near-monopoly position in the CF treatment market.
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 3 stocks. BestLagging
Financial Scorecard
VRTX 2XOMA 1REGN 1XOMA4/6 metricsREGN6/7 metricsVRTX5/9 metricsVRTX5/6 metricsVRTX leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). XOMA leads in 1 (Financial Metrics). 2 tied.
Financial Metrics (TTM)
REGN is the larger business by revenue, generating $14.3B annually — 304.5x XOMA's $47M. XOMA is the more profitable business, keeping 41.1% of every revenue dollar as net income compared to VRTX's 31.3%. On growth, XOMA holds the edge at +29.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | XOMAXOMA Royalty Corp. | VRTXVertex Pharmaceut… | REGNRegeneron Pharmac… |
|---|---|---|---|
| RevenueTrailing 12 months | $47M | $11.7B | $14.3B |
| EBITDAEarnings before interest/tax | $22M | $4.2B | $4.2B |
| Net IncomeAfter-tax profit | $19M | $3.7B | $4.5B |
| Free Cash FlowCash after capex | $5M | $3.3B | $3.2B |
| Gross MarginGross profit ÷ Revenue | +93.8% | +86.3% | +86.3% |
| Operating MarginEBIT ÷ Revenue | +4.1% | +34.1% | +25.7% |
| Net MarginNet income ÷ Revenue | +41.1% | +31.3% | +31.4% |
| FCF MarginFCF ÷ Revenue | +11.4% | +28.5% | +22.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +29.9% | +11.0% | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +144.0% | +4.7% | -2.5% |
Valuation Metrics
At 19.0x trailing earnings, REGN trades at a 39% valuation discount to VRTX's 31.2x P/E. Adjusting for growth (PEG ratio), REGN offers better value at 3.00x vs VRTX's 3.77x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | XOMAXOMA Royalty Corp. | VRTXVertex Pharmaceut… | REGNRegeneron Pharmac… |
|---|---|---|---|
| Market CapShares × price | $316M | $121.4B | $108.4B |
| Enterprise ValueMkt cap + debt − cash | $334M | $120.0B | $92.2B |
| Trailing P/EPrice ÷ TTM EPS | -16.03x | 31.19x | 18.99x |
| Forward P/EPrice ÷ next-FY EPS est. | 39.71x | 24.68x | 17.38x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.77x | 3.00x |
| EV / EBITDAEnterprise value multiple | — | 25.60x | 21.83x |
| Price / SalesMarket cap ÷ Revenue | 11.10x | 10.11x | 7.55x |
| Price / BookPrice ÷ Book value/share | 3.78x | 6.61x | 2.74x |
| Price / FCFMarket cap ÷ FCF | — | 38.01x | 26.56x |
Profitability & Efficiency
VRTX delivers a 21.2% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $14 for REGN. REGN carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to XOMA's 1.46x. On the Piotroski fundamental quality scale (0–9), REGN scores 7/9 vs XOMA's 4/9, reflecting strong financial health.
| Metric | XOMAXOMA Royalty Corp. | VRTXVertex Pharmaceut… | REGNRegeneron Pharmac… |
|---|---|---|---|
| ROE (TTM)Return on equity | +17.9% | +21.2% | +14.4% |
| ROA (TTM)Return on assets | +7.3% | +14.8% | +11.1% |
| ROICReturn on invested capital | -37.6% | +22.8% | +12.4% |
| ROCEReturn on capital employed | -19.4% | +23.0% | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 7 |
| Debt / EquityFinancial leverage | 1.46x | 0.20x | 0.09x |
| Net DebtTotal debt minus cash | $18M | $3.7B | -$16.2B |
| Cash & Equiv.Liquid assets | $102M | $5.1B | $18.9B |
| Total DebtShort + long-term debt | $119M | $3.7B | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | 0.67x | 348.55x | 120.42x |
Total Returns (with DRIP)
A $10,000 investment in VRTX five years ago would be worth $22,544 today (with dividends reinvested), compared to $7,158 for XOMA. Over the past 12 months, XOMA leads with a +22.5% total return vs VRTX's -2.8%. The 3-year compound annual growth rate (CAGR) favors VRTX at 17.9% vs REGN's 0.5% — a key indicator of consistent wealth creation.
| Metric | XOMAXOMA Royalty Corp. | VRTXVertex Pharmaceut… | REGNRegeneron Pharmac… |
|---|---|---|---|
| YTD ReturnYear-to-date | -5.5% | +5.7% | +1.6% |
| 1-Year ReturnPast 12 months | +22.5% | -2.8% | +15.1% |
| 3-Year ReturnCumulative with dividends | +23.9% | +63.9% | +1.5% |
| 5-Year ReturnCumulative with dividends | -28.4% | +125.4% | +71.6% |
| 10-Year ReturnCumulative with dividends | +46.9% | +425.4% | +94.0% |
| CAGR (3Y)Annualised 3-year return | +7.4% | +17.9% | +0.5% |
Risk & Volatility
VRTX is the less volatile stock with a 0.44 beta — it tends to amplify market swings less than XOMA's 0.82 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. REGN currently trades 95.9% from its 52-week high vs XOMA's 66.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XOMAXOMA Royalty Corp. | VRTXVertex Pharmaceut… | REGNRegeneron Pharmac… |
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.82x | 0.44x | 0.58x |
| 52-Week HighHighest price in past year | $39.92 | $519.68 | $821.11 |
| 52-Week LowLowest price in past year | $18.35 | $362.50 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +66.3% | +92.0% | +95.9% |
| RSI (14)Momentum oscillator 0–100 | 49.0 | 50.0 | 47.5 |
| Avg Volume (50D)Average daily shares traded | 482K | 1.4M | 762K |
Analyst Outlook
Analyst consensus: XOMA as "Buy", VRTX as "Buy", REGN as "Buy". Consensus price targets imply 158.0% upside for XOMA (target: $68) vs 8.8% for REGN (target: $857). For income investors, XOMA offers the higher dividend yield at 1.77% vs REGN's 0.43%.
| Metric | XOMAXOMA Royalty Corp. | VRTXVertex Pharmaceut… | REGNRegeneron Pharmac… |
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $68.25 | $545.08 | $857.17 |
| # AnalystsCovering analysts | 10 | 55 | 48 |
| Dividend YieldAnnual dividend ÷ price | +1.8% | — | +0.4% |
| Dividend StreakConsecutive years of raises | 0 | — | 1 |
| Dividend / ShareAnnual DPS | $0.47 | — | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | +1.7% | +3.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | 100 | 113.81 | +13.8% |
| Vertex Pharmaceutic… (VRTX) | 100 | 204.81 | +104.8% |
| Regeneron Pharmaceu… (REGN) | 100 | 161.99 | +62.0% |
Vertex Pharmaceutic… (VRTX) returned +125% over 5 years vs XOMA Royalty Corp. (XOMA)'s -28%. A $10,000 investment in VRTX 5 years ago would be worth $22,544 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | $6M | $28M | +412.0% |
| Vertex Pharmaceutic… (VRTX) | $1.7B | $12.0B | +605.1% |
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
Vertex Pharmaceuticals Incorporated's revenue grew from $1.7B (2016) to $12.0B (2025) — a 24.2% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | -9.6% | -48.5% | -404.3% |
| Vertex Pharmaceutic… (VRTX) | -6.6% | 32.9% | +600.4% |
| Regeneron Pharmaceu… (REGN) | 18.4% | 31.4% | +70.5% |
Vertex Pharmaceuticals Incorporated's net margin went from -7% (2016) to 33% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | 48.8 | 32.1 | -34.2% |
| Vertex Pharmaceutic… (VRTX) | 144.1 | 29.6 | -79.5% |
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
XOMA Royalty Corp. has traded in a 32x–57x P/E range over 3 years; current trailing P/E is ~-16x. Vertex Pharmaceuticals Incorporated has traded in a 21x–144x P/E range over 8 years; current trailing P/E is ~31x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| XOMA Royalty Corp. (XOMA) | -8.89 | -1.65 | +81.4% |
| Vertex Pharmaceutic… (VRTX) | -0.46 | 15.32 | +3430.4% |
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
Vertex Pharmaceuticals Incorporated's EPS grew from $-0.46 (2016) to $15.32 (2025).
Chart 6Free Cash Flow — 5 Years
XOMA Royalty Corp. generated $-14M FCF in 2024 (-260% vs 2021). Vertex Pharmaceuticals Incorporated generated $3B FCF in 2025 (+33% vs 2021).
XOMA vs VRTX vs REGN: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is XOMA or VRTX or REGN a better buy right now?
Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 19.0x trailing P/E (17.4x forward), making it the more compelling value choice. Analysts rate XOMA Royalty Corp. (XOMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — XOMA or VRTX or REGN?
On trailing P/E, Regeneron Pharmaceuticals, Inc. (REGN) is the cheapest at 19.0x versus Vertex Pharmaceuticals Incorporated at 31.2x. On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 17.4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Regeneron Pharmaceuticals, Inc. wins at 2.75x versus Vertex Pharmaceuticals Incorporated's 2.98x.
03Which is the better long-term investment — XOMA or VRTX or REGN?
Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +125.4%, compared to -28.4% for XOMA Royalty Corp. (XOMA). A $10,000 investment in VRTX five years ago would be worth approximately $23K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VRTX returned +425.4% versus XOMA's +46.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — XOMA or VRTX or REGN?
By beta (market sensitivity over 5 years), Vertex Pharmaceuticals Incorporated (VRTX) is the lower-risk stock at 0.44β versus XOMA Royalty Corp.'s 0.82β — meaning XOMA is approximately 85% more volatile than VRTX relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 146% for XOMA Royalty Corp. — giving it more financial flexibility in a downturn.
05Which has better profit margins — XOMA or VRTX or REGN?
Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.9% net margin versus -48.5% for XOMA Royalty Corp. — meaning it keeps 32.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39.1% versus -140.3% for XOMA. At the gross margin level — before operating expenses — XOMA leads at 99.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is XOMA or VRTX or REGN more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Regeneron Pharmaceuticals, Inc. (REGN) is the more undervalued stock at a PEG of 2.75x versus Vertex Pharmaceuticals Incorporated's 2.98x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Regeneron Pharmaceuticals, Inc. (REGN) trades at 17.4x forward P/E versus 39.7x for XOMA Royalty Corp. — 22.3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XOMA: 158.0% to $68.25.
07Which pays a better dividend — XOMA or VRTX or REGN?
In this comparison, XOMA (1.8% yield), REGN (0.4% yield) pay a dividend. VRTX does not pay a meaningful dividend and should not be held primarily for income.
08Is XOMA or VRTX or REGN better for a retirement portfolio?
For long-horizon retirement investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.44), +425.4% 10Y return). Both have compounded well over 10 years (VRTX: +425.4%, REGN: +94.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between XOMA and VRTX and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. XOMA pays a dividend while VRTX, REGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.